Very common adverse Common adverse reactions reactions ≥ 10% of patients ≥ 1 to < 10% of patients Weight increased or decreased (G3/ 4:
Väga sagedased kõrvaltoimed ≥ 10% patsientidest Kehakaalu tõus või langus (3. / 4. aste: